Dapagliflozin reduced left ventricular mass index early into treatment in patients with nondialysis-dependent CKD, regardless of disease etiology and cardiovascular history. Dapagliflozin reduces left ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The eGFR slope improved in all but one patient not on a ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at observing the clinical effects of sacubitril/valsartan combined with dapagliflozin ...

A woman reaching for a prescription bottle in a medicine cabinet Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials. Dapagliflozin reduces the risk of ...

Among a small cohort of healthy Korean male volunteers, evogliptin combined with empagliflozin or dapagliflozin had no significant effects on the pharmacokinetics (PK) of each drug. In healthy male ...

Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...

A multicentre trial in China finds that combining SGLT-2 inhibitors with calorie restriction improves remission, weight loss, and metabolic health without added adverse effects Study: Dapagliflozin ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In the kidney, SGLT2 reabsorbs approximately ...